Both vaccines are designed to induce humoral and cellular immune responses that target the circumsporozoite protein antigen of Plasmodium falciparum.
Under the grant, Protein Potential will use its expertise in the production of high-quality recombinant proteins to produce CSP that will be combined with one or more adjuvants, while Aduro will use its platform technology based on live-attenuated Listeria monocytogenes to engineer a strain that expresses recombinant CSP.
Protein Potential founder and president Kim Lee Sim said, "The partnership with Aduro is an exciting opportunity to explore the synergy of these two approaches to stimulate immunity and move rapidly to the clinic with a malaria vaccine."
Aduro BioTech chairman and CEO Stephen Isaacs said, "The collaboration with Protein Potential and its sister company, Sanaria Inc., combine outstanding technology with world-class translational medicine."